Jack L. Sloane

Jack L. Sloane

Auto-generated profile, based on publicly available information

Jack L. Sloane

Bristol Myers Squibb, 250 Water St., Cambridge, Massachusetts 02446, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2017 in Science
Verified
Journal Article
Closed access
PDF file
PWPaul A. Wender
Paul A. Wender
CHClayton T. Hardman
Clayton T. Hardman
SHStephen Ho
Stephen Ho
MJMatthew S. Jeffreys
Matthew S. Jeffreys
JMJana K. Maclaren
Jana K. Maclaren
MSMatthew C. Stevens
Matthew C. Stevens
A gram-scale route to bryostatin: Scientists once accumulated 14 tons of the red, bushy, tufted sea creature Bugula neritina to extract 18 grams of bryostatin 1. The macrocyclic organic compound is under study for treatment of HIV, cancer, and Alzheimer's disease but has proven frustratingly scarce. Wender et al. report a 29-step chemical synthesis of bryostatin 1 that proceeds in 4.8% overall yield and provides gram quantities of the compound (see the Perspective by Lanman). Intermediates along the pathway can be straightforwardly modified to produce analogs, two of which were prepared en route and studied in vitro. Science , this issue p. 218 ; see also p. 166

20 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CHClayton Hardman
Clayton Hardman
SHStephen Ho
Stephen Ho
ASAkira Shimizu
Akira Shimizu
QLQuang Luu-Nguyen
Quang Luu-Nguyen
JSJack L. Sloane
Jack L. Sloane
PWPaul A. Wender
Paul A. Wender
Bryostatin 1 is a marine natural product under investigation for HIV/AIDS eradication, the treatment of neurological disorders, and enhanced CAR T/NK cell immunotherapy. Despite its promising activity, bryostatin 1 is neither evolved nor optimized for the treatment of human disease. Here we report the design, synthesis, and biological evaluation of several close-in analogs of bryostatin 1. Using a function-oriented synthesis approach, we synthesize a series of bryostatin analogs designed to maintain affinity for bryostatin’s target protein kinase C (PKC) while enabling exploration of their divergent biological functions. Our late-stage diversification strategy provides efficient access to a library of bryostatin analogs, which per our design retain affinity for PKC but exhibit variable PKC translocation kinetics. We further demonstrate that select analogs potently increase cell surface expression of CD22, a promising CAR T cell target for the treatment of leukemias, highlighting the clinical potential of bryostatin analogs for enhancing targeted immunotherapies.

25 August 2023 in ACS Catalysis
Verified
Journal Article
Closed access
JGJunqing Guo
Junqing Guo
DNDerek Norris
Derek Norris
ARAntonio Ramirez
Antonio Ramirez
JSJack L. Sloane
Jack L. Sloane
ESEric M. Simmons
Eric M. Simmons
TSTrevor C. Sherwood
Trevor C. Sherwood

3 August 2022 in Organic Letters
Verified
Journal Article
Closed access
ACAnthony N. Cauley
Anthony N. Cauley
ARAntonio Ramirez
Antonio Ramirez
CBChandan L. Barhate
Chandan L. Barhate
ADAndrew F. Donnell
Andrew F. Donnell
PKPurnima Khandelwal
Purnima Khandelwal
ESEric M. Simmons
Eric M. Simmons

6 June 2023 in Organic Letters
Verified
Journal Article
Closed access
JSJack L. Sloane
Jack L. Sloane
ASAnna Beatriz Santos
Anna Beatriz Santos
ESEric M. Simmons
Eric M. Simmons
TSTrevor C. Sherwood
Trevor C. Sherwood